

# **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM D NOTICE OF SALE OF SECURITIES **PURSUANT TO REGULATION D** SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

<i>\rangle</i> _	,								
	OMB APPROVAL								
	OMB Number:	3235-0076							
	Expires:	April 30, 2008							
-	Estimated average burden								
- 1	hours per response	16.00							



Name of Offering (☐ check if this is an amendment and name has changed, and indicate change.)  Sale of units consisting of common stock and warrants
Filing under (Check box(es) that apply): ☐ Rule 504 ☐ Rule 505 ☐ Rule 506 ☐ Section 4(6) ☐ ULOE
Type of Filing: ☐ New Filing ☐ Amendment
A. BASIC IDENTIFICATION DATA
1. Enter the information requested about the issuer
Name of Issuer ( check if this is an amendment and name has changed, and indicate change.)  Novelos Therapeutics, Inc.
Address of Executive Offices (Number and Street, City, State, Zip Code) One Gateway Center, Suite 504, Newton, MA 02458  Telephone Number (Including Area Code) 617-244-1616
Address of Principal Business Operations (Number and Street, City, State, Zip Code)  (if different from Executive Offices)  Telephone Number (Including Area Code)
Brief Description of Business Development stage company established to commercialize drugs for the treatment of cancer and hepatitis
Type of Business Organization
☐ business trust ☐ limited partnership, to be formed
Actual or Estimated Date of Incorporation or Organization:    O   6   9   6
General Instructions
Federal:
Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).
When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.
Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.
Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.
Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.
Filing Fee: There is no federal filing fee.
State:
This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on the ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

**ATTENTION** Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on

the filing of a federal notice.

A. BASIC IDENTIFIC	CATION DATA							
Enter the information requested for the following:			i i					
<ul> <li>Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial own power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the</li> </ul>								
<ul> <li>Each executive officer and director of corporate issuers are issuers; and</li> </ul>	nd of corporate gene	ral managing partne	rs of partner	ship				
<ul> <li>Each general and managing partnership of partnership is:</li> </ul>	suers.		i					
Check Box(es) that Apply:	Executive Officer	☑ Director	General a					
Full Name (Last name first, if individual)  Harry S. Palmin								
Business or Residence Address (Number and Street, City, State, Zip Cc/o Novelos Therapeutics, Inc., One Gateway Center, Suite 504, Ne				, , , , , ,				
Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☒	Executive Officer	☑ Director	General a					
Full Name (Last name first, if individual) Simyon Palmin			:					
Business or Residence Address (Number and Street, City, State, Zip Coco Novelos Therapeutics, Inc., One Gateway Center, Suite 504, Ne								
	Executive Officer	□ Director	☐ General a Managing Pa					
Full Name (Last name first, if individual)  Mark Balazovsky								
Business or Residence Address (Number and Street, City, State, Zip Coco Novelos Therapeutics, Inc., One Gateway Center, Suite 504, Ne								
Check Box(es) that Apply: Promoter Beneficial Owner	Executive Officer	□ Director	General a					
Full Name (Last name first, if individual) Sim Fass, Ph.D.								
Business or Residence Address (Number and Street, City, State, Zip Coco Novelos Therapeutics, Inc., One Gateway Center, Suite 504, Ne								
Check Box(es) that Apply:	Executive Officer	□ Director	General a					
Full Name (Last name first, if individual)  David B. McWilliams								
Business or Residence Address (Number and Street, City, State, Zip Coco Novelos Therapeutics, Inc., One Gateway Center, Suite 504, New York (Number and Street, City, State, Zip Coco Novelos Therapeutics, Inc., One Gateway Center, Suite 504, New York (Number and Street, City, State, Zip Coco Novelos Therapeutics, Inc., One Gateway Center, Suite 504, New York (Number and Street, City, State, Zip Coco Novelos Therapeutics, Inc., One Gateway Center, Suite 504, New York (Number and Street, City, State, Zip Coco Novelos Therapeutics, Inc., One Gateway Center, Suite 504, New York (Number and Street, City, State, Zip Coco Novelos Therapeutics, Inc., One Gateway Center, Suite 504, New York (Number and Street, City, State, Zip Coco Novelos Therapeutics, Inc., One Gateway Center, Suite 504, New York (Number and Street, City, State, Zip Coco Novelos Therapeutics, Inc., One Gateway Center, Suite 504, New York (Number and Street, City, State, Zip Coco Novelos Therapeutics, Inc., One Gateway Center, Suite 504, New York (Number and Street, City, State, Zip Coco Novelos Therapeutics, Inc., One Gateway Center, Suite 504, New York (Number and Street, City, State, Zip Coco Novelos Therapeutics)								
	Executive Officer	⊠ Director	General :					
Full Name (Last name first, if individual)  Howard M. Schneider								
Business or Residence Address (Number and Street, City, State, Zip Coc/o Novelos Therapeutics, Inc., One Gateway Center, Suite 504, Ne								
Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐	Executive Officer	Director	General :					
Full Name (Last name first, if individual)  Wood River Trust								
Business or Residence Address (Number and Street, City, State, Zip Cocolo Michael C. Doyle, co-trustee, c/o Stewart Management Compart Wilmington, DE 19801		uilding, 1007 Oran	ge Street,					
Check Box(es) that Apply: Promoter Beneficial Owner	Executive Officer	Director	☐ General Managing Pa					
Full Name (Last name first, if individual)	_			· · · · · · · · · · · · · · · · · · ·				
Business or Residence Address (Number and Street, City, State, Zip Co	ode)							
(Use blank sheet, or copy and use additional	al copies of this sheet, a	s necessary.)						

B3080648.1 2 of 8

		1								
	B. INFORMATION ABOUT OFFERING		No							
1.	, , , , , , , , , , , , , , , , , , , ,									
	Answer also in Appendix, Column 2, if filing under ULOE.	1								
2.	,									
3.	3. Does the offering permit joint ownership of a single unit?									
4.	Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchases in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.	4 4 1								
	l Name (Last name first, if individual) rcer Capital Ltd.									
Bus <b>45</b>	siness or Residence Address (Number and Street, City, State, Zip Code) Broadway, 30 <sup>th</sup> Floor, New York, NY 10006									
	me of Associated Broker or Dealer rcer Capital Ltd.									
	ttes in Which Person Listed Has Solicited or Intends to Solicit Purchasers neck "All States" or check individual States)	All S	tates							
(Ci [AL] [IL] [MT] [RI]	□ [AK] □ [AZ] □ [AR] □ [CA] □ [CO] □ [CT] □ [DE] □ [DC] □ [FI] □ [GA] □ [HI]         □ [IN] □ [IA] □ [KS] □ [KY] □ [LA] □ [ME] □ [MD] □ [MA] ☒ [MI] □ [MN] ☒ [MS]		(ID) (MO) (PA) (PR)							
	l Name (Last name first, if individual) nance Investments, Inc.									
Bus <b>880</b>	siness or Residence Address (Number and Street, City, State, Zip Code) 3 <b>Third Avenue, 12<sup>th</sup> Floor, New York, NY 10022</b>									
	me of Associated Broker or Dealer Inance Investments, Inc.									
	ates in Which Person Listed Has Solicited or Intends to Solicit Purchasers neck "All States" or check individual States)	ΔΙΙ Ο	tates							
(C) [AL] [IL] [MT] [RI]	□ [AK]       □ [AZ]       □ [AZ]       □ [CA]       □ [CO]       □ [CT]       □ [DE]       □ [DC]       □ [FI]       ☒ [GA]       □ [HI]         ☒ [IN]       □ [IA]       □ [KS]       □ [KY]       □ [LA]       □ [ME]       □ [MD]       □ [MA]       ☒ [MI]       □ [MN]       □ [MS]		[ID] [MO] [PA] [PR]							
	ll Name (Last name first, if individual) e Attachment A									
Bus	siness or Residence Address (Number and Street, City, State, Zip Code)									
Na	me of Associated Broker or Dealer									
	etes in Which Person Listed Has Solicited or Intends to Solicit Purchasers heck "All States" or check individual States)	ΔΙΙΟ	tates							
(Cr [AL] [IL] [MT] [RI] [RI]			[ID] [MO] [PA] [PR] [PR]							
(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)										

3 of 8

B3080648.1

Attachment A

The following individuals have received finders fees for introducing certain investors in the Offering to the Company:

	Chassman	Reilly	Freedman	Mazo	Mazo	Mathias	Lisser	Fortunato	Last
	Margie	Jim	Michael	Marina	Andrey	Bruce	Lev	Jennifer	First
	445 W 23rd Street #16E, New York, NY 10011	4417 Downing Place Way, Mount Pleasant SC 29466	189 West 89th Street, Suite 11F, New York, NY 10024	1550 Worcester Road, Apt 208, Framingham, MA 01702	52 Highland Terrace, Needham, MA 02494	57 Aspen Road, Sharon, MA 02067	2780 Ocean Avenue, Oceanside, NY 11572	101 Moore Road, Sudbury, MA 01776	Address
	CA, NY	IL, NY	FL, NJ, NY	MA	MA	MA	NY	FL, MA, NJ, NY	Investors' States
↔	\$	↔	↔	↔	↔	\$	↔	↔	
166,500	52,000	8,000	\$ 62,500	3,000	5,000	12,000	14,000	10,000	otal Fee

#### 1. Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \( \square\) and indicate in the columns below the amounts of the securities offered for exchange and already exchanged. Aggregate Amount Already Type of Security Offering Price Sold Debt..... \$0 Equity (including warrants to purchase common stock)..... \$5,000,000 \$<u>11,500,000</u> □ Common ☐ Preferred Convertible Securities (including warrants) ...... \$0 \$0 Partnership Interests \$0 \$0 Other (Specify \_\_\_\_\_\_) ..... \$0 \$0 Total ..... \$11,500,000 \$5,000,000 Answer also in Appendix, Column 3, if filing under ULOE. Enter the number of accredited and non-accredited investors who have purchased securities in Aggregate this offering and the aggregate dollar amounts of their purchases. For offerings under Rule Number of Dollar Amount 504, indicate the number of persons who have purchased securities and the aggregate dollar Investors of Purchases amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero." Accredited Investors ..... 110 \$5,000,000 0 \$0 Non-accredited Investors ..... Total (for filing under Rule 504 only) ...... Answer also in Appendix, Column 4, if filing under ULOE. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1. Type of Dollar Amount Type of offering Security Sold Rule 505. ..... Regulation A. Rule 504. Total..... Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate. Transfer Agent's Fees. Printing and Engraving Costs. Legal Fees. \$110,000 Accounting Fees. Engineering Fees. Other Expenses (identify) (10% of offering proceeds to placement agents including \$166,500 as finders' fees) \$500,000 Total \$650,000 Enter the difference between the aggregate offering price given in response to Part C-Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer." ...... \$4<sup>i</sup>,350,000

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS							
<ol> <li>Indicate below the amount of the adjuste used for each of the purposes shown. It estimate and check the box to the left of equal the adjusted gross proceeds to the above.</li> </ol>	f the amount for any purp the estimate. The total o	ose is not known, furni of the payments listed i	sh an must				
			Payment Officer				
			Directors Affiliate	s, & Payments To			
Salaries and fees			🗀 \$ <u>0</u>	□ \$ <u>0</u>			
Purchase of real estate			D \$ <u>0</u>	☐ \$ <u>O</u>			
Purchase, rental or leasing and inst	allation of machinery and	equipment	🗀 \$ <u>0</u>	☐ \$ <u>0</u>			
Construction or leasing of plant buil Acquisition of other business (includent that may be used in exchange for the	ling the value of securities assets or securities of	s involved in this offeri another issuer pursuar	ng nt	☐ \$ <u>O</u>			
to a merger)	••••••	***************************************	🗆 \$ <u>0</u>	□ \$ <u>0</u>			
Repayment of indebtedness			🗆 \$ <u>0</u>	<b>⋈</b> \$ <u>970,000</u>			
Working capital	***************************************		🗆 \$0	\$ <u>3,380,000</u>			
Other (specify):				<u> </u>			
Column Totals			🗀 \$ <u>0</u>	☐ \$ <u>4,350,000</u>			
Total Payments Listed (column tota	ls added)		🛛 \$4	¥,350,000			
	D. FEDERAL	SIGNATURE					
The issuer has duly caused this notice to be following signature constitutes an undertakin request of its staff, the information furnished Issuer (Print or Type)  Novelos Therapeutics, Inc.	g by the issuer to furnish	to the U.S. Securities	and Exchange Comr	nission, upon written			
		5 (000					
Name of Signer (Print or Type)	Title of Signer (Print or	• • •					
Harry S. Palmin	President, Acting CEC						
	ATTE	NTION					
Intentional misstatements or omission			ns. (See 18 U.S.C. 1	001.)			

## APPENDIX

1		2	3			4			5
	Intend to r accre investors	to sell non- edited s in State i-Item1)	Type of Security and aggregate offering price offered in state (Part C-Item 1)	Type of investor and amount purchased in State (Part C-Item 2)					ification ate ULOE attach ation of granted) Item 1)
				Number of Accredited		Number of Non- Accredited			
State AL	Yes	No 🗆		Investors	Amount \$	Investors	Amount \$	Yes	No 🗆
AK				· · · · · · · · · · · · · · · · · · ·	<del>_</del>		 \$		
<b></b>			····		 \$		 \$	<del> </del>	
AZ					\$ \$				
AR			*				\$		
CA				1	\$ <u>150,000</u>	0	\$ <u>0</u>		
СО							\$		
СТ					<u> </u>		<u> </u>		
DE					\$				
DC					\$		\$		
FL			*	7	\$ <u>550,000</u>	0	<u>\$0</u>		$\boxtimes$
GA		$\boxtimes$	*	1	\$ <u>25,000</u>	0	\$ <u>0</u>		
н					\$		\$		
ID					\$		\$		
IL		$\boxtimes$	*	3	\$ <u>275,000</u>	0	\$ <u>0</u>		$\boxtimes$
IN					\$		\$		
IA					\$		\$		
KS					\$		\$		
KY					\$		\$		
LA					\$		\$		
ME					\$		\$		
MD					\$		\$		
MA			*	21	\$ <u>625,000</u>	0	\$ <u>0</u>		$\boxtimes$
MI					\$		\$		
MN		⊠	*	3	\$250,000	0	\$ <u>0</u>		$\boxtimes$
MS		☒	*	1	\$ <u>25,000</u>	0	\$ <u>0</u>		
МО					\$		\$		

<sup>\*</sup> Units consisting of common stock and common stock purchase warrants. \$11,500,000 is the aggregate offering price in each state.

B3080648.1 7 of 8

## 'APPENDIX

1		2	3		4	1		1 1	5
	to r accre investors	to sell non- edited s in State l-Item1)	Type of Security and aggregate offering price offered in state (Part C-Item 1)	Type of investor and amount purchased in State (Part C-Item 2)				Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)	
State	Yes	No		Number of Accredited Investors	Amount	Number of Non- Accredited Investors	Amount	Yes	No
MT					\$		\$		
NE					\$		\$		
NV					\$		\$		
NH					\$		\$		
NJ		Ø	*	10	\$ <u>550,000</u>	0	\$ <u>0</u>		$\boxtimes$
NM					\$		\$		
NY		⊠	*	29	\$ <u>1,325,000</u>	0	\$ <u>0</u>		$\boxtimes$
NC		⊠	*	2	\$ <u>75,000</u>	0	\$ <u>0</u>		$\boxtimes$
ND					\$		\$		
ОН		$\boxtimes$	*	1	\$ <u>25,000</u>	0	\$ <u>0</u>		$\boxtimes$
ОК				,	\$		\$		
OR					\$		\$		
PA		×	*	1	\$ <u>25,000</u>	0	\$ <u>0</u>		$\boxtimes$
RI					\$		\$		
sc					\$		\$		
SD					\$		\$		
TN		$\boxtimes$	*	1	\$ <u>25,000</u>	0	\$ <u>0</u>		⊠
TX		×	*	2	\$ <u>100,000</u>	0	\$ <u>0</u>		$\boxtimes$
UT					\$		\$		
VT					\$		\$		
VA			*	2	\$ <u>100,000</u>	0	\$ <u>0</u>		$\boxtimes$
WA					\$		\$	<u></u> '	
WV					\$		\$		
WI					\$		\$		
WY					\$		\$		
PR					\$		\$		
Other			*	25	\$ <u>875,000</u>	0	\$ <u>0</u>		$\boxtimes$

<sup>\*</sup> Units consisting of common stock and common stock purchase warrants. \$11,500,000 is the aggregate offering price in each state.

8 of 8